; (B) reduce reliance on the People’s Republic of China for such products and ingredients; and (C) facilitate cooperation with the governments of other countries in a concerted effort to make significant strategic investments in research, development, and manufacturing of such products and ingredients. (3) Report required (A) In general Not later than 180 days after the date of the enactment of this Act, the President shall submit to the appropriate congressional committees a report on the strategy required by paragraph (1). (B) Elements The report required in paragraph (1) shall include— (i) a description of the extent of the engagement of the United States International Development Finance Corporation with the governments of other countries to promote shared investment in and development of finished pharmaceutical products and active pharmaceutical ingredients; and (ii) a description of the work of the United States Trade Representative to engage with the governments of those countries to decrease trade barriers for the development, production, refinement, and transportation of such products and ingredients. (c) Investments in pharmaceutical supply chain resiliency (1) In general In support of the strategy required by subsection (b), the United States International Development Finance Corporation shall prioritize providing support under title II of the Better Utilization of Investments Leading to Development Act of 2018 ( 22 U.S.C. 9621 et seq. ) for manufacturing and production of finished pharmaceutical products and active pharmaceutical ingredients, including projects that— (A) contribute to the development of a more reliable and secure supply chain for such products and ingredients; (B) reduce reliance on the People’s Republic of China for such products and ingredients